Pharmacological treatment of CPVT-type CaM mutations may require RyR2 stabilization, or at least, blunting membrane electrical response to spontaneous Ca2+ release events. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.